Home

electronic Self-Administered Psoriasis Area and Severity Index

 

eSA-PASI

 

Psoriasis self-assessment made easy and quick

 

esapasi ios

iOS version
esapasi android

Android version
esapasi web

Web version (German)
esapasi pdf
Illustrative PDF (coming soon)
esapasi pdf or
Original PDF (coming soon)

What is the SA-PASI

 

The Self-Administered Psoriasis Area and Severity Index (SAPASI) is intended to measure the psoriasis severity by patients themselves. The SAPASI evaluates the area affected by psoriasis and captures its redness, thickness and scaliness. A regular SAPASI assessment may help to continuously monitor the progression of the disease.

How was the SA-PASI developed?

 

The SA-PASI was developed at the Bowman Gray School of Medicine of Wake Forest University in the USA. The SA-PASI is a modified version of the original PASI, which requires trained staff for the measurement. Instead of the calculation of the involved Body Surface Area (BSA) by trained personnel, a line-drawing silhouette of the front and back is marked by the patient to estimate the involved body area. In the electronic version of the SAPASI, the body surface area is calculated using the patient's palm, with one palm representing approximately 1% of the body surface area. This is done by four body regions (head, trunk, back and legs). Since its original development the SAPASI was validated in multiple studies and showed high agreement with the original and well accepted PASI. The electronic version of the SAPASI is currently validated at the Institute for Health Services Research in Dermatology and Nursing at the University Medical Center Hamburg Eppendorf. 

 

How to use the SA-PASI

 

The SAPASI is a measurement tool for self-assessment that can be filled out by the patient himself. The questionnaire is self-explanatory and consists out of two parts.

 

First, three questions, assessing the severity of a typical plaque by its redness, thickness and scaliness.

 

esapasi image

Second, the affected area of the body is determined. The assessment is made with the help of the patient's palm. For each body region (head, trunk, back and legs), the number of palms that fit on the affected skin areas is counted. The final sum score is derived by a combination of the body area involved and the severity of an average plaque. The score is automatically calculated in the DermaTools application.

 

esapasi image2

Following you can find the versions of the eSA-PASI

esapasi ios
iOS version
esapasi android
Android version
esapasi web
Web version
esapasi pdf

Illustrative PDF (coming soon)

esapasi pdf or

Original PDF (coming soon)

psoriasisimage

Plate XXIII, Psoriasis. Crocker 1896
Credit: Wellcome Library, London

About Psoriasis

 

Psoriasis is a long-lasting autoimmune disease known by its abnormal patches of skin (red, itchy and even scaly).

 

“Psoriasis is a chronic inflammatory disease, with an incidence in Western industrialized countries of 1.5 % to 3 %. It represents a great burden to the patient due to marked loss of quality of life, therapy-refractory course and frequent side effects of therapy.”

 

Prof. Dr. med. med. Matthias Augustin

Features

patient icon epasi

PATIENT-CENTRED

SA-PASI is intended to be used by a patient or a caregiver.

calculate icon epasi

QUICK ASSESSMENT

Save your time with eSA-PASI. In only a few minutes you can get your SA-PASI score without doing any calculations.

use icon epasi

USER-FRIENDLY

eSA-PASI is straightforward to use, thanks to the simple instructions and visual analogue scales.

global icon epasi

VALIDATED

Since its original development the SA-PASI was validated in multiple studies and showed good agreement with the original and well accepted PASI.

patient icon epasi

MONITOR EVOLUTION

A regular SA-PASI assessment may help to continuously monitor the progression of the disease and determine the effect of a treatment.  

platform icon epasi

RESPONSIVE AND MULTI-DEVICE

Your eSA-PASI is always a couple of touches or clicks away, available on desktop, tablet, phone and other devices.

References

 

Fleischer AB Jr, Feldman SR, Dekle CL. The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial. J Dermatol. 1999 Apr;26(4):210-5. doi: 10.1111/j.1346-8138.1999.tb03458.x. PMID: 10343464.

Our Further Tools

eeasi web
eflqa web
eiga web
eitch web
edlqi web
enappa web
epain web
epasi web
epbi web
epbik web
epbiw web
epgaforacne web
epgaforpsoriasis web
epsosat web
esaeasi web
esapasi web
escorad web
ewoundqol web
dapsa en web

Our Partners

uke 1
psonet
cles88irj0bil0gf5qbmkfcio clahx75m800wlq891u93kod65 cvderm
ddg2
bvd
cles91jyt00w4tqf506r77am2 imgpsh fullsize anim 1222